KR870008879A - 티아제핀류의 제조 방법 - Google Patents

티아제핀류의 제조 방법 Download PDF

Info

Publication number
KR870008879A
KR870008879A KR870002852A KR870002852A KR870008879A KR 870008879 A KR870008879 A KR 870008879A KR 870002852 A KR870002852 A KR 870002852A KR 870002852 A KR870002852 A KR 870002852A KR 870008879 A KR870008879 A KR 870008879A
Authority
KR
South Korea
Prior art keywords
formula
manufacturing
compound
thiazine
reacting
Prior art date
Application number
KR870002852A
Other languages
English (en)
Other versions
KR900001868B1 (ko
Inventor
존 워로워 에드워드
마틴 미글러 버나드
Original Assignee
원본미기재
임페리얼 케미칼 인더스트리스 어메리카스 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595359&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR870008879(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 임페리얼 케미칼 인더스트리스 어메리카스 인코오포레이티드 filed Critical 원본미기재
Publication of KR870008879A publication Critical patent/KR870008879A/ko
Application granted granted Critical
Publication of KR900001868B1 publication Critical patent/KR900001868B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

티아제핀류의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. (a) 하기식(Ⅳ)의 이미노클로라이드를 1-히드록시에틸 피페라진과 반응시키거나;
    (b) 하기식(Ⅶ)의 티오에테르를 하기식(Ⅴ)의 피페라진과 반응시킨뒤 염기형의 하기식(Ⅱ)의 화합물이 산출되면 산과 반응시켜 염을 생성하고 식(Ⅱ)의 화합물이 염이면 중학시키는 것으로 구성된 하기식(Ⅱ) 화합물의 제조방법.
    R1은 C1-C3-알킬, F 또는 C1이고,
    g는 0,1 또는 2이며,
    상기식에서 R1은 S-R1이 이탈기가 되도록 선택되어 지는데 일례로(1-3C)알킬.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870002852A 1986-03-27 1987-03-27 티아제핀 및 그의 제조방법 KR900001868B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8607684 1986-03-27
GB8607684 1986-03-27
GB868607684A GB8607684D0 (en) 1986-03-27 1986-03-27 Thiazepine compounds

Publications (2)

Publication Number Publication Date
KR870008879A true KR870008879A (ko) 1987-10-21
KR900001868B1 KR900001868B1 (ko) 1990-03-26

Family

ID=10595359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870002852A KR900001868B1 (ko) 1986-03-27 1987-03-27 티아제핀 및 그의 제조방법

Country Status (31)

Country Link
US (1) US4879288A (ko)
EP (1) EP0240228B1 (ko)
JP (1) JPH064606B2 (ko)
KR (1) KR900001868B1 (ko)
AR (1) AR242198A1 (ko)
AT (1) ATE58132T1 (ko)
AU (1) AU593336B2 (ko)
BG (1) BG61365B2 (ko)
CA (1) CA1288428C (ko)
CY (2) CY1706A (ko)
DD (1) DD259403A5 (ko)
DE (3) DE10075016I2 (ko)
DK (1) DK174618B1 (ko)
ES (1) ES2019379T4 (ko)
FI (1) FI86059C (ko)
GB (2) GB8607684D0 (ko)
GR (1) GR3001061T3 (ko)
HK (1) HK85393A (ko)
HU (1) HU201062B (ko)
IE (1) IE59864B1 (ko)
IL (1) IL81923A (ko)
LU (1) LU90593I2 (ko)
MW (1) MW2087A1 (ko)
NL (1) NL980022I2 (ko)
NO (2) NO168771C (ko)
NZ (1) NZ219788A (ko)
PH (1) PH26516A (ko)
PT (1) PT84569B (ko)
ZA (1) ZA871940B (ko)
ZM (1) ZM2987A1 (ko)
ZW (1) ZW5787A1 (ko)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
DE3827447A1 (de) * 1988-08-12 1990-04-26 Basf Ag Polyazofarbstoffe und deren zwischenprodukte
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9716161D0 (en) 1997-08-01 1997-10-08 Zeneca Ltd Process
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
JP2004516271A (ja) * 2000-12-20 2004-06-03 アストラゼネカ・アクチエボラーグ 治療法
EP1359919B1 (en) 2001-02-06 2007-04-25 AstraZeneca AB Use of quetiapine for the treatment of ***e dependence
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
DK1458888T3 (da) * 2001-12-10 2011-06-20 Novartis Ag Fremgangsmåder til behandling af psykose og skizofreni baseret på polymorfier i CNTF-genet
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
EP2000141A1 (en) 2002-03-20 2008-12-10 Teva Pharmaceutical Industries Ltd. Methods for preparing crystalline quetiapine hemifumarate
KR100707050B1 (ko) 2002-11-28 2007-04-13 에스케이 주식회사 10Ｈ-디벤조[ｂ,ｆ][1,4]티아제핀-11-온의 제조방법
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
CA2516646A1 (en) * 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
AU2003216705A1 (en) * 2003-03-03 2004-09-28 Hetero Drugs Limited Novel polymorphs of quetiapine fumarate
EP1611138A1 (en) * 2003-04-07 2006-01-04 Hetero Drugs Limited A novel crystalline form of dorzolamide hydrochloride
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
ATE477803T1 (de) * 2003-07-02 2010-09-15 Astrazeneca Ab Metabolit von quetiapine
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
ES2223294B2 (es) * 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20050080072A1 (en) * 2003-09-01 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a thiazepine derivative
EP1664009B1 (en) * 2003-09-23 2011-01-19 Fermion Oy Preparation method for quetiapine
CN101005829A (zh) * 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005063254A2 (en) 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR101038389B1 (ko) * 2004-06-23 2011-06-01 에스케이바이오팜 주식회사 11-(4-[2-(2-히드록시에톡시)에틸]-1-피페라지닐)-디벤조[ｂ,ｆ][1,4]티아제핀의 제조방법
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
EA010977B1 (ru) * 2004-08-24 2008-12-30 Янссен Фармацевтика Н.В. Бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
WO2006027789A1 (en) * 2004-09-08 2006-03-16 Jubilant Organosys Limited PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20060063927A1 (en) * 2004-09-22 2006-03-23 Olga Etlin Processes for preparing quetiapine and salts thereof
WO2006035293A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Salts of quetiapine
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
EP1841751A1 (en) * 2005-01-24 2007-10-10 IPCA Laboratories Limited INDUSTRIAL PREPARATION OF 11-(4-(2-(2-HYDROXYETHOXY ETHYL)-1-PIPERAZINYL)DIBENZO (b,f)-1(1, 4)THIAZEPINE
AU2006209212B2 (en) * 2005-01-26 2011-02-17 Elan Pharma International Limited Controlled release compositions comprising an antipsychotic agent
ES2234447B1 (es) * 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
JP2008533142A (ja) * 2005-03-18 2008-08-21 アボット・ラボラトリーズ α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
US7488821B2 (en) * 2005-04-04 2009-02-10 Divi's Laboratories Limited Polymorph of Quetiapine fumarate and a process for its preparation
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
US8048876B2 (en) 2005-04-21 2011-11-01 Medichem S.A. Process for preparing quetiapine and quetiapine fumarate
AR056321A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070072840A1 (en) * 2005-05-30 2007-03-29 Pandya Bhargav Polymorphic forms of quetiapine
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
GB0516603D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists
US8044038B2 (en) 2005-09-30 2011-10-25 Fermion Oy Crystallization process of quetiapine hemifumarate
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
WO2009151393A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
WO2009151392A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
WO2007102074A2 (en) * 2006-03-07 2007-09-13 Cadila Healthcare Limited Salts of quetiapine
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CZ300451B6 (cs) * 2006-07-03 2009-05-20 Farmak, A. S. Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
CN101610774B (zh) * 2006-11-03 2012-04-04 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
PT103884A (pt) 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
WO2008066750A1 (en) 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
CN101616585A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
EP2124908A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USE
WO2008110337A2 (en) 2007-03-09 2008-09-18 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
CN100569761C (zh) * 2007-04-18 2009-12-16 湖南洞庭药业股份有限公司 制备药物纯富马酸喹硫平的生产方法
WO2009004480A2 (en) * 2007-05-07 2009-01-08 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
HU230144B1 (hu) * 2007-06-12 2015-09-28 Richter Gedeon Nyrt. Eljárás quetiapin előállítására
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
CA2711395A1 (en) * 2008-01-31 2009-08-06 Fermion Oy A process for the preparation of quetiapine
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090264408A1 (en) * 2008-04-17 2009-10-22 Gulati Inder Extended release dosage forms of quetiapine
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EA201001889A1 (ru) * 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
AU2009265099A1 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising Quetiapine
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
JP2012502915A (ja) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド てんかんを治療する組成物及び方法
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2403841A1 (en) 2009-03-04 2012-01-11 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate
EP2233130A1 (en) 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
US20110223207A1 (en) 2010-03-11 2011-09-15 Travis Mickle Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
PL2608670T3 (pl) 2010-08-23 2019-05-31 Alkermes Pharma Ireland Ltd Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
WO2012064349A1 (en) 2010-11-09 2012-05-18 Forest Carl A Sleep aid composition and method
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
WO2013074048A2 (en) 2011-08-08 2013-05-23 Mahmut Bilgic Tablet forms comprising quetiapine fumarate
CN102391208A (zh) * 2011-10-25 2012-03-28 湖南洞庭药业股份有限公司 富马酸喹硫平的新晶形i及其制备方法
WO2013095312A1 (en) 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprising quetiapine fumarate
WO2013100879A1 (en) 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical compositions comprising quetiapine
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN104016945B (zh) * 2014-05-27 2016-06-29 渭南畅通药化科技有限公司 一种半富马酸喹硫平的制备方法
IL256354B (en) 2015-06-19 2022-09-01 Agenebio Inc History of benzodiazepines, preparations and their use for the treatment of cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020025579A1 (en) 2018-07-31 2020-02-06 Medichem, S.A. Solid dosage form of quetiapine fumarate
EP4213817A1 (en) 2020-09-21 2023-07-26 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
CN113698363A (zh) * 2021-09-15 2021-11-26 苏州敬业医药化工有限公司 一种11-哌嗪-二苯并[b,f][1,4]硫氮杂卓盐酸盐的纯化方法
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
FR127F (ko) * 1964-03-27
FR90378E (ko) * 1965-03-26 1968-02-14
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
CH539044A (de) * 1967-10-06 1973-08-31 Gnii Orch Poluproduktov I Kras Verfahren zur Herstellung quaternärer Ammoniumsalze von 1,3-Bis-(aminomethyl)-imidazolidonen
GB1262509A (en) * 1969-06-20 1972-02-02 Science Union & Cie New tricyclic derivatives and process for their preparation
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
BE792426A (fr) * 1971-12-09 1973-06-07 Wander Ag Dr A Nouveaux derives de la dibenzo(b,f)(1,4)thiazepine, leur preparation etleur application comme medicaments
CH569730A5 (ko) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH624682A5 (ko) * 1976-11-10 1981-08-14 Sandoz Ag
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines

Also Published As

Publication number Publication date
NL980022I2 (nl) 1998-11-02
IE870700L (en) 1987-09-27
HK85393A (en) 1993-08-27
IL81923A (en) 1991-03-10
PT84569A (en) 1987-04-01
DE10075017I1 (de) 2000-09-21
PH26516A (en) 1992-08-07
FI871137A0 (fi) 1987-03-16
AU7045987A (en) 1987-10-01
CY1706A (en) 1994-01-14
DE3765969D1 (en) 1990-12-13
ZW5787A1 (en) 1988-11-02
NO2001009I1 (no) 2001-06-25
JPH064606B2 (ja) 1994-01-19
NO871267L (no) 1987-09-28
CY98045I1 (el) 2010-07-28
EP0240228B1 (en) 1990-11-07
US4879288A (en) 1989-11-07
ZA871940B (en) 1987-11-25
ES2019379T4 (es) 2015-08-12
DK158587D0 (da) 1987-03-27
AR242198A1 (es) 1993-03-31
FI86059C (fi) 1992-07-10
EP0240228A1 (en) 1987-10-07
DK158587A (da) 1987-09-28
NL980022I1 (nl) 1998-10-01
HU201062B (en) 1990-09-28
NO168771C (no) 1992-04-01
FI871137A (fi) 1987-09-28
GR3001061T3 (en) 1992-03-20
PT84569B (pt) 1989-11-30
MW2087A1 (en) 1987-11-11
FI86059B (fi) 1992-03-31
DK174618B1 (da) 2003-07-21
ZM2987A1 (en) 1991-02-28
ES2019379B3 (es) 1991-06-16
BG61365B2 (bg) 1997-06-30
IE59864B1 (en) 1994-04-20
AU593336B2 (en) 1990-02-08
GB8706949D0 (en) 1987-04-29
NO871267D0 (no) 1987-03-26
ATE58132T1 (de) 1990-11-15
GB8607684D0 (en) 1986-04-30
HUT47568A (en) 1989-03-28
DE10075016I2 (de) 2002-10-10
DD259403A5 (de) 1988-08-24
IL81923A0 (en) 1987-10-20
JPS638378A (ja) 1988-01-14
CA1288428C (en) 1991-09-03
LU90593I2 (fr) 2000-08-07
NZ219788A (en) 1990-02-26
CY98045I2 (el) 2010-07-28
KR900001868B1 (ko) 1990-03-26
NO168771B (no) 1991-12-23

Similar Documents

Publication Publication Date Title
KR870008879A (ko) 티아제핀류의 제조 방법
KR850000406A (ko) 4-클로로-2-페닐이미다졸-5-아세트산유도체의 제조방법
KR860001110A (ko) 항균제 ⅱ의 제법
KR850006415A (ko) 항균제의 제조방법
KR840000544A (ko) 항균성 나프탈리딘 또는 퀴놀린 화합물의 염을 제조하는 방법
FR2436150A1 (fr) Derives de 3'',4''-diacyltylosine utiles comme medicaments
KR850002460A (ko) 카르바메이트 화합물의 제조방법
KR850004470A (ko) 유기 화합물의 제조방법
KR840003606A (ko) 판테놀 유도체의 제제 판테놀 유도체의 제제방법
KR850002979A (ko) 1,2,3-트리티안화합물의 신규 제조방법
KR850001663A (ko) 살충 및 응애류 박멸제 조성물
KR830001644A (ko) 아릴알킬-및 아릴옥시알킬포스포네이트의 제조방법
KR840007656A (ko) 살충제 조성물
KR930700433A (ko) 신규 디술피드 화합물
KR840005153A (ko) 신규 유기인산염의 농약의 제조방법
KR870007908A (ko) 인덴류 화합물의 제조방법
KR840002351A (ko) 치오알카노일-카르니틴의 제조방법 및 이를함유하는 점액분해 용약으로 제조된 조성물
KR870006068A (ko) 살충성 유기인 화합물 및 그의 제조방법
KR860006474A (ko) 유기 인산염의 제조방법
KR860008996A (ko) 구아니디노 티아졸 화합물의 제조방법
FR2361368A1 (fr) Derives diphenyliques de composes de la polyamine comportant une fraction piperidinique
KR840005318A (ko) 살균제 조성물
KR880011174A (ko) 세펨 유도체의 제조방법
KR840000504A (ko) N- 페닐피라졸 유도체의 제조방법
KR890002309A (ko) 유기 포스파이트 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070112

Year of fee payment: 18

EXPY Expiration of term